Document and Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts and Other Receivables, Net, Current Accounts receivable, net Prepaid Expense, Current Prepaid expenses Inventory, Finished Goods, Gross Inventory Other Assets, Current Other current assets Assets, Current Total current assets Assets, Noncurrent [Abstract] Non-current assets Accounts Receivable, after Allowance for Credit Loss, Noncurrent Non-current accounts receivable, net Other Assets, Noncurrent Other non-current assets, net of amortization Assets, Noncurrent Total non-current assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Deficit Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Contract with Customer, Liability, Current Contract liability - current Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non-current liabilities Contract with Customer, Liability, Noncurrent Contract liability - long-term Liabilities, Noncurrent Total non-current liabilities Liabilities Total liabilities Stockholders' Equity Shareholders' equity/(deficit) Common Stock, Value, Issued Common stock, no par value; unlimited shares authorized; 34,541 shares issued and outstanding (2025 - 34,163) Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Equity, Attributable to Parent Balance, ending Balance, beginning Total shareholders' equity/(deficit) Liabilities and Equity Total liabilities and shareholders' equity/(deficit) Common Stock, No Par Value Common stock, no par value Common Stock, Shares Authorized, Unlimited [Fixed List] Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Consolidated Statements of Operations Revenues Net product revenues PEDMARK product sales, net Operating Expenses [Abstract] Operating expenses: The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Cost of product sales Research and Development Expense Research and development Selling and Marketing Expense Selling and marketing General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) (Loss)/income from operations Nonoperating Income (Expense) [Abstract] Other income/(expense) Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Unrealized foreign exchange gain/(loss) Amortization of Debt Issuance Costs and Discounts Amortization expense Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Unrealized Loss on Available for Sale Securities Unrealized loss on securities Investment Income, Interest Interest income Interest Expense, Debt Interest expense Nonoperating Income (Expense) Total other expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income tax Net loss Net loss Net loss Net loss Earnings Per Share, Basic Basic net loss per common share Earnings Per Share, Diluted Diluted net loss per common share Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares, basic Weighted-average number of common shares outstanding basic Weighted-average common shares, dilutive Weighted Average Number of Shares Outstanding, Diluted Weighted-average number of common shares outstanding diluted Consolidated Statements of Shareholders' Equity Statement [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Statement [Line Items] Shares, Outstanding Balance, ending (shares) Balance, beginning (shares) APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Equity-based compensation - employees APIC, Share-Based Payment Arrangement, Recognition and Exercise Stock-based compensation Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of Options Exercised Exercise of stock options (shares) Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock release Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Restricted stock release (shares) Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in)/provided by operating activities: Accounts Receivable, Credit Loss Expense (Reversal) Allowance for credit losses Amortization of Acquisition Costs Amortization of contract asset Amortization of Debt Discount (Premium) Amortization of debt discount Debt Securities, Available-for-Sale, Unrealized Loss Unrealized loss on securities Share-Based Payment Arrangement, Noncash Expense Equity-based compensation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expenses, Other Prepaid expenses Increase (Decrease) in Inventories Inventory Increase (Decrease) in Other Current Assets Other current assets Increase (Decrease) in Other Noncurrent Assets Other non-current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued liabilities Increase (Decrease) in Contract with Customer, Liability Contract liability Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Net cash (used in)/provided by operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Proceeds from Stock Options Exercised Proceeds from issuance of stock options Issuance of shares, options exercise Payment, Tax Withholding, Share-Based Payment Arrangement Cash paid for taxes on restricted share release Net Cash Provided by (Used in) Financing Activities Net cash provided by/(used in) by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents - End of year Cash and cash equivalents - Beginning of year Nature of Business and Liquidity Nature of Operations [Text Block] Nature of Business and Liquidity Significant Accounting Policies Significant Accounting Policies [Text Block] Significant Accounting Policies Loss per Share Earnings Per Share [Text Block] Loss per Share Equity [Text Block] Stockholders' Equity Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies License Agreement Collaborative Arrangement Disclosure [Text Block] License Agreement Segment Reporting Segment Reporting Disclosure [Text Block] Segment Reporting Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss. Allowance for Trade Credit Losses [Policy Text Block] Credit Losses Segment Reporting, Policy [Policy Text Block] Segment and Geographic Information Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Inventory, Policy [Policy Text Block] Inventory Revenue [Policy Text Block] Revenue Recognition Disclosure of accounting policy with regard to license agreements. License Agreement, Policy [Policy Text Block] License Agreements Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block] Net Product Revenue Disclosure of accounting policy for product sales discounts and allowances. Product Sales Discounts and Allowances [Policy Text Block] Product Sales Discounts and Allowances Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block] Trade Receivables Cost of Goods and Service [Policy Text Block] Cost of Products Sold Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Fair Value of Financial Instruments, Policy [Policy Text Block] Financial Instruments Research and Development Expense, Policy [Policy Text Block] Research and Development Costs and Investment Tax Credits Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk Income Tax, Policy [Policy Text Block] Income Taxes Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Earnings Per Share, Policy [Policy Text Block] Income/(Loss) Per Share Disclosure of accounting policy with regard to reclassifications. Reclassifications, Policy [Policy Text Block] Reclassifications New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. Schedule of PEDMARK Revenues, Net [Table Text Block] Schedule of PEDMARK Revenues, Net Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. Schedule of PEDMARK Revenues, Discounts and Allowances [Table Text Block] Schedule of PEDMARK Revenues, Discounts and Allowances Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Net Loss Per Share Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Warrants to Purchase Common Stock Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Schedule of Recognized Expense Related to Employee Option Exercises Share-Based Payment Arrangement, Activity [Table Text Block] Schedule of Share-Based Compensation, Stock Option Activity Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-Based Compensation, Stock Option Volatility Measurements Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Restricted Share Unit Activity Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis Schedule of Long-Term Debt Instruments [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Exclusive Licensing Agreement [Member] Licensing Agreement Counterparty Name [Axis] Counterparty Name [Domain] Norgine LTD. Norgine LTD [Member] Norgine Ltd. Debt Instrument [Line Items] Nature of Business and Going Concern [Line Items] Amount of funding received through license agreements. License agreement funding received Amount of potential milestone funding available through license agreements. License agreement funding, potential milestone payments Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Warrant [Member] Warrants to purchase common shares Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Warrants to Purchase Common Shares [Member] Warrants to Purchase Common Shares Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met. Restricted Stock Options [Member] Restricted Stock Options Restricted share units to obtain common shares Information pertaining to convertible notes that are convertible into shares of common stock. Convertible Notes To Common Stock [Member] Convertible Notes Convertible Debt to Purchase Common Shares Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time. Options to Purchase Common Shares [Member] Common Stock Options Options to Purchase Common Shares Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Accounts Receivable, Allowance for Credit Loss, Current Allowance for doubtful accounts Discount given to customers for prompt payment. Discounts for prompt payment The company's expectation for the percentage of prompt payment discounts customers will earn. Percentage of prompt payment discounts expected to pay out Money Market Funds, at Carrying Value Money market investments Cash Cash, FDIC Insured Amount FDIC insured amount Class of Warrant or Right, Outstanding Warrants outstanding, ending balance Warrants outstanding, beginning balance Warrants outstanding Class of Warrant or Right, Exercise Price of Warrants or Rights Weighted-average exercise price of warrants outstanding, end of period Weighted-average exercise price of warrants outstanding, beginning of period Warrants exercise price Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from EPS Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Domain] Information relating to PEDMARK. PEDMARK Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue Benchmark [Member] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Disaggregation of Revenue [Line Items] Amount of gross revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Gross product revenue Amount of cash inflow from customers for revenue related transactions that are refundable to the customers and do not meet the criteria for revenue recognition. Refunds, discounts and allowances Discounts and allowances Number of customers with concentration risk. Number Of Customers With Concentration Risk Serves as the "benchmark" percentage of revenues contributed by customers deemed to be significant. Contribution of revenue percentage denoting significant customers Scenario [Axis] Scenario [Domain] Represents information relating to chargebacks, discounts for prompt payment and other allowances related to product sales. Chargebacks, Discounts for Prompt pay and Other allowances Represents information pertaining to rebates, customer fees/credits and co-pay assistance related to product sales discounts and allowances. Rebates, Customer Fees/Credits and Co-pay Assistance Provision for aggregate discounts and allowances provided to customers and offset to gross revenues earned. Provision for discounts and allowances Provision for discounts and allowances, ending balance Provision for discounts and allowances, beginning balance Amount of expense (reversal of expense) for expected discounts and allowances on gross sales. Discounts and allowances, provision for current period sales Current period Payments made against the Company's provision for product sales discounts and allowances. Discounts and allowances, payments and customer credits issued Payments and customer credits issued Inventory, Current [Table] Inventory [Line Items] Manufacturing costs related to PEDMARK and capitalized to inventory, amount reclassified as cost.of products sold. Manufacturing costs capitalized to inventory, cost of products sold Capitalized inventory costs reclassified to cost of products sold Manufacturing costs related to PEDMARK and capitalized to inventory. Manufacturing costs capitalized to inventory Manufacturing costs related to PEDMARK and capitalized to inventory, amount classified as work-in-process. Manufacturing costs capitalized to inventory, work-in-process Manufacturing costs related to PEDMARK and capitalized to inventory, amount classified as finished goods. Manufacturing costs capitalized to inventory, finished goods Numerator [Abstract] Numerator: Denominator [Abstract] Denominator: Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Dilutive effect of stock options Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted share units. Dilutive effect of restricted share units Weighted Average Number of Shares Outstanding, Diluted, Adjustment Incremental dilutive shares Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stockholders Equity Note [Table] Stockholders Equity Note [Table] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Employee Options Plan Name [Axis] Plan Name [Domain] Represents information pertaining to Equity Incentive Plan. Equity Incentive Plan Represents information pertaining to Equity Incentive Plan amendments. Equity Incentive Plan Amendment [Member] Equity Incentive Plan Amendment Stockholders Equity Note [Line Items] Stockholders Equity Note [Line Items] Authorized capital stock Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Options Outstanding at Ending Number of Options Outstanding at Beginning Options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Number of Options Granted Percentage of Common Shares Outstanding Percentage Of Common Shares Outstanding Shares issuable under Stock Option Plan, as percent of shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Number of options fully vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares issuable under Stock Option Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Life (years) Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Warrants issued Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants exercised Recognized Employee Expense [Table] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Recognized Employee Expense [Line Items] Stock or Unit Option Plan Expense Total option expense recognized Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Vesting Tranche I Share-Based Payment Arrangement, Tranche Two [Member] Vesting Tranche II Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Vesting percentage APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Restricted stock unit expense recognized Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] US Denominated RSU's Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested shares, end of period Unvested shares, beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) RSU's awarded Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other Shares released Grantee Status [Axis] Grantee Status [Domain] Share-Based Payment Arrangement, Employee [Member] Employees Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected life Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-average Exercise Price Outstanding at Ending Weighted-average Exercise Price outstanding at Beginning Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average Exercise Price Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-average Exercise Price Exercised Collaborative Arrangement and Arrangement Other than Collaborative [Table] Represents information pertaining to license agreement. License agreement Represents information pertaining to Processa Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Quoted Price in Active Markets for Identical Instruments Level 1 Money Market Accounts Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs Level 2 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Common Stock, Value, Outstanding Processa common shares Represents the number of shares entitled to receive under license agreement. Collaborative Arrangement, Shares to be Issued Shares to be issued under agreement Fair Value, Assets and Liabilities Measured on Recurring Basis [Table] Fair Value Assets and Liabilities Measured On Recurring Basis [Table] Information reported for cash held in Canadian funds, and translated into US dollars. Canadian funds translated into USD Canadian Funds (Translated to USD) Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value Assets and Liabilities Measured On Recurring Basis [Line Items] Other Commitments [Table] Other Commitments [Axis] Other Commitments [Domain] Information relating to the Company's lease contingencies. Lease Contingencies Information relating to ongoing litigation with CIPLA Ltd. and CIPLA USA over their submission to the FDA for a generic version of the Company's trademarked medication, PEDMARK. CIPLA ANDA Litigation Represents information related to executive severance payments. Executive Severance Title and Position [Axis] Title and Position [Domain] Chief Executive Officer [Member] Jeff Hackman, CEO Robert Andrade Geographical [Axis] Geographical [Domain] Represents information pertaining to leases in Triangle Park, North Carolina. Triangle Park, North Carolina Represents information pertaining to leases in Hoboken, New Jersey. Hoboken, New Jersey Represents information pertaining to the Company's Office Service Agreement with Regus to lease office space. Office Service Agreement Represents information pertaining to the Company's second Office Service Agreement with Regus to lease office space. Second Office Service Agreement [Member] Second Office Service Agreement Other Commitments [Line Items] Operating Lease, Expense Monthly lease expense Represents number of scheduled payment increases over the duration of the lease agreement. Operating lease, number of scheduled payment increases Days notice required to terminate lease agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Operating lease, days notice required to terminate agreement Amount of operating lease penalties and contingent payments due. Operating lease, penalties and contingent payments payable Security Deposit Liability Security deposit Days following the receipt of a Notice Letter in which the Company can formally file a patent infringement suit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Days following receipt of Notice Letter to file patent infringement suit Duration of FDA's ability to give final approval to proposed products that reference PEDMARK subsequent to the filing of a patent infringement suit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Duration of FDA's ability to give final approval to proposed products that reference PEDMARK Duration of PEDMARK's exclusivity period due to Orphan Drug Exclusivity status, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. PEDMARK's Orphan Drug Exclusivity period Registration Payment Arrangement, Maximum Potential Consideration Severance payments due Represents number of severance payments following executive's termination. Number of severance payments Term over which severance payments will be made in the event of employment termination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Term of executive severance in event of termination Severance payment term Period of months (at the executive's then-current base salary) used to determine initial severance payment in the event of employment termination "without cause," in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Executive severance, months of current base salary payable Equivalent months of base salary used to determine initial severance payment amount Disclosure of information about the company's licensing agreements. Licensing Agreement [Table] License Agreement [Line items] Amount of incremental costs paid as a part of the Company's license agreement. Incremental costs paid Amount of incremental costs capitalized to other non-current assets as a part of the Company's license agreement. Incremental costs capitalized to other non-current assets Contract with Customer, Liability